Reata Pharmaceuticals, Inc.
RETANASDAQHealthcare
$172.36
+$0.04(+0.02%)
Market Cap$6.6B
P/E Ratio—
52W High$172.46
52W Low$21.83
Reata Pharmaceuticals, Inc. (RETA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RETA · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.22M | $11.49M | $9.02M | $26.52M | $53.59M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $124.40M | $0.00M |
| Gross Profit | $2.22M | $11.49M | $9.02M | ($97.88M) | $53.59M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | -369.13% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $169.84M | $155.99M | $159.08M | $128.11M | $97.29M |
| G&A Expenses | $109.28M | $99.00M | $75.13M | $58.30M | $32.75M |
| Total Operating Expenses | $280.25M | $256.20M | $235.34M | $187.34M | $130.47M |
| Operating Income | ($270.15M) | ($244.71M) | ($226.32M) | ($285.22M) | ($76.88M) |
| Operating Margin %(computed) | — | — | — | — | -143.46% |
| Interest Income | $5.99M | $0.18M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $41.77M | $53.25M | $36.78M | $11.20M | $6.18M |
| Income Before Tax | ($311.93M) | ($297.84M) | ($270.24M) | ($290.16M) | ($80.52M) |
| Income Tax Expense | ($0.03M) | ($0.45M) | ($22.49M) | $0.01M | $0.03M |
| Net Income | ($311.90M) | ($297.39M) | ($247.75M) | ($290.17M) | ($80.55M) |
| Net Margin %(computed) | — | — | — | — | -150.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.59 | $-8.19 | $-7.35 | $-9.54 | $-2.91 |
| Wtd Avg Shares | 36.32M | 36.32M | 33.71M | 30.41M | 27.70M |
| EBITDA | ($269.02M) | ($243.50M) | ($232.32M) | ($278.03M) | ($73.91M) |
| EBITDA Margin %(computed) | — | — | — | — | -137.93% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Reata Pharmaceuticals, Inc. data
About Reata Pharmaceuticals, Inc. (RETA) Income Statement
Reata Pharmaceuticals, Inc. (RETA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, RETA reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.31B) — a net profit margin of -14074.95%.
Frequently asked questions
RETA · 4 questionsReata Pharmaceuticals, Inc. (RETA) reported revenue of $0.00B for 2022, down 80.7% year-over-year.
RETA revenueRETA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09